



Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences

November 12, 2019

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 12, 2019-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the following healthcare investor conferences in November:

- **Stifel 2019 Healthcare Conference**

Lotte New York Palace Hotel
New York, N.Y.
Tuesday, November 19, 2019
Presentation time: 4:45 p.m. (ET)

- **Jefferies 2019 London Healthcare Conference**

London, U.K.
Thursday, November 21, 2019
Presentation time: 11:40 a.m. (ET)/4:40 p.m. (GMT)

Live audio webcasts of these presentations can be accessed on the Investor Relations section of the Aldeyra Therapeutics website at <https://ir.aldeyra.com>. Replays will be available following the live events and will be archived on the website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191112005614/en/>

Source: Aldeyra Therapeutics, Inc.

Corporate Contact:

David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcnullin@aldeyra.com

Investor & Media Contact:

Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com